Hypoxia-inducible factor prolyl hydroxylase inhibitors suppressed thymic stromal lymphopoietin production and allergic responses in a mouse air-pouch-type ovalbumin sensitization model
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110127 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Ryosuke Segawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578,…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Prolyl-Hydroxylase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Atopic dermatitis (AD) is an allergic skin disease, triggered by excessive type 2 immune reactions. Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine that induces type 2 immune response through dendritic cell activation. Therefore, TSLP inhibitors may serve as novel antiallergic drugs. Hypoxia-inducible factor (HIF) activation in the epithelia contributes to several homeostatic phenomena, such as re-epithelialization. However, the effects of HIF activation on TSLP production and immune activation in the skin remain unclear. In this study, we found that selective HIF prolyl hydroxylase inhibitors (PHD inhibitors), which induce HIF activation, suppressed TSLP production in a mouse ovalbumin (OVA) sensitization model. PHD inhibitors also suppressed the production of tumor necrosis factor-alpha (TNF-α), which is a major inducer of TSLP production, in this mouse model and in a macrophage cell line. Consistent with these findings, PHD inhibitors suppressed OVA-specific IgE levels in the serum and OVA-induced allergic responses. Furthermore, we found a direct suppressive effect on TSLP expression in a human keratinocyte cell line mediated by HIF activation. Taken together, our findings suggest that PHD inhibitors exert antiallergic effects by suppressing TSLP production. Controlling the HIF activation system has therapeutic potential in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan.
- Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. Electronic address: noriyasu.hirasawa.c7@tohoku.ac.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Segawa, R., Kyoda, T., Yagisawa, M., Muramatsu, T., Hiratsuka, M., & Hirasawa, N. (2023). Hypoxia-inducible factor prolyl hydroxylase inhibitors suppressed thymic stromal lymphopoietin production and allergic responses in a mouse air-pouch-type ovalbumin sensitization model. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110127
Vancouver
Segawa R, Kyoda T, Yagisawa M, Muramatsu T, Hiratsuka M, Hirasawa N. Hypoxia-inducible factor prolyl hydroxylase inhibitors suppressed thymic stromal lymphopoietin production and allergic responses in a mouse air-pouch-type ovalbumin sensitization model. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110127
BibTeX
@article{Segawa2023,
author = {Segawa, Ryosuke and Kyoda, Takuya and Yagisawa, Makiko and Muramatsu, Tadanobu and Hiratsuka, Masahiro and Hirasawa, Noriyasu},
title = {Hypoxia-inducible factor prolyl hydroxylase inhibitors suppressed thymic stromal lymphopoietin production and allergic responses in a mouse air-pouch-type ovalbumin sensitization model},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110127}
}
EUVIMED